Xeltis AG

Xeltis is a clinical-stage European medical device company leveraging breakthrough science to transform heart valve therapy. Xeltis is revolutionizing the treatment of heart valve disease. The companys restorative heart valves enable the patients own body to naturally form a new heart valve through a therapeutic approach called Endogenous Tissue Restoration (ETR). With ETR, the patients natural healing system develops tissue that pervades Xeltis heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.

ETR is enabled by the porous structure of Xeltis heart valves, which are made of bioabsorbable polymers, based on Nobel prize awarded science.